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Context/Objective: Current diagnostic criteria for polycystic ovary syndrome (PCOS) have gener-
ated distinct PCOS phenotypes, based on the different combinations of diagnostic features found
in each patient. Our aim was to assess whether either each single diagnostic feature or their
combinations into the PCOS phenotypes may predict insulin resistance in these women.
Patients/Design: A total of 137 consecutive Caucasian women with PCOS, diagnosed by the Rot-
terdam criteria, underwent accurate assessment of diagnostic and metabolic features. Insulin
sensitivity was measured by the glucose clamp technique.
Results: Among women with PCOS, 84.7% had hyperandrogenism, 84.7% had chronic oligoan-
ovulation, and 89% had polycystic ovaries. According to the individual combinations of these
features, 69.4% of women had the classic phenotype, 15.3% had the ovulatory phenotype, and
15.3% had the normoandrogenic phenotype. Most subjects (71.4%) were insulin resistant. How-
ever, insulin resistance frequency differed among phenotypes, being 80.4%, 65.0%, and 38.1%,
respectively, in the 3 subgroups (P .001). Although none of the PCOS diagnostic features per se
was associated with the impairment in insulin action, after adjustment for covariates, the classic
phenotype and, to a lesser extent, the ovulatory phenotype were independently associated with
insulin resistance, whereas the normoandrogenic phenotype was not. Metabolic syndrome fre-
quency was also different among phenotypes (P  .030).
Conclusions: There is a scale of metabolic risk among women with PCOS. Although no single
diagnostic features of PCOS are independently associated with insulin resistance, their combina-
tions, which define PCOS phenotypes, may allow physicians to establish which women should
undergo metabolic screening. In metabolic terms, women belonging to the normoandrogenic
phenotype behave as a separate group. (J Clin Endocrinol Metab 98: E628–E637, 2013)
Polycystic ovary syndrome (PCOS) is a common con-dition ofwomen in the reproductive age,with a num-
ber of potential clinical consequences, including an in-
creased risk for infertility, dysfunctional bleeding,
endometrial hyperplasia, obesity, and insulin resistance
with theassociatedmetabolic alterations.Moreover, these
subjects have an increased risk of endometrial carcinoma
and possibly cardiovascular disease later in life (1, 2).
Unfortunately, there are no unequivocal criteria for di-
agnosing PCOS, and its definition remains controversial.
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According to the 2003 Rotterdam European Society of
HumanReproduction and Embryology/American Society
for Reproductive Medicine (ESHRE/ASRM) consensus
workshop (3), PCOSmay be diagnosed by the presence of
at least 2 of 3 cardinal features: hyperandrogenism,
chronic oligoanovulation, and polycystic ovary (PCO)
morphology, after exclusion of secondary causes. This
definition widened the previous diagnostic boundaries of
the syndrome, set out in 1990 by a National Institutes of
Health consensus conference (4), with two major conse-
quences: (1) PCOS prevalence has risen substantially,
from 6–8% to 12–20% (5, 6); and (2) according to the
various possible combinations of the 3 above-mentioned
diagnostic features in each individual subject, adoption of
theRotterdamcriteriahas introduceddifferentPCOSphe-
notypes, subsequently named classic (characterized by hy-
perandrogenism and oligoanovulation, with or without
PCOmorphology, and corresponding to the previousNa-
tional Institutes ofHealth definition), ovulatory (hyperan-
drogenism and PCO), and normoandrogenic (oligoan-
ovulation and PCO).
In2006, theRotterdamcriteriawerebrought intoques-
tion by the Androgen Excess and PCOS Society (AE-
PCOS). The document summarizing this discussion con-
firmed that PCOS diagnosis should be based on the 3
clinical features indicated by the ESHRE/ASRM consen-
sus. However, it established a hierarchical order of these
features, in that hyperandrogenism was considered fun-
damental, combined with oligoanovulation and/or PCO
morphology (1). As a consequence, theAE-PCOSposition
excluded the possibility of a normoandrogenic PCOSphe-
notype. The debate on these issues is still ongoing.
One major implication of the increased clinical heter-
ogeneity underpinning adoption of the Rotterdam diag-
nostic criteria comes from the hypothesis that the different
PCOS phenotypes could diverge in terms of insulin resis-
tance (7). If confirmed, this hypothesis suggests that these
patients should be screened differently and possibly
treated differently for the metabolic dysfunction. On the
other hand, these findings may actually reflect disparities
in obesity, which seems to be associated differently with
the various PCOS phenotypes (8).
A better understanding of these issues may also have
significant theoretical implications, because it was argued
that if the various PCOSphenotypes have the same overall
morbidity in terms of insulin resistance, then the conclu-
sion that they all really reflect the same overall syndrome
would be strongly supported (1).
Insulin resistance is not a disease per se, but rather it is
a common physiological abnormality increasing the like-
lihood that several alterations may occur (9). In this re-
gard, it is noteworthy that insulin resistance probably
plays a pathogenetic role in PCOS (10). Moreover, it is a
forerunner of several metabolic alterations, which also
occur frequently in these subjects. It has been estimated
that about 70%ofwomenwith PCOS are insulin resistant
(11, 12). However, the true prevalence of this phenome-
non in subjects with PCOS and it stratification among the
different PCOSphenotypes remainunclear issues, because
interpretationof available studies is constrainedby several
limitations, particularly with regard to methods used to
assess insulin sensitivity.
The hyperinsulinemic-euglycemic clamp is the best
available technique for measurement of in vivo insulin
sensitivity (13). However, it is complex and expensive.
Therefore, epidemiological studies generally rely on sur-
rogate indices, based on measurement of insulin and glu-
cose levels (14). Unfortunately, although all these indirect
estimates correlate with the direct measures of insulin ac-
tion, the degree of correlation is limited (15–18). More-
over, most of these studies used routine testosterone as-
says. These methods generally have poor sensitivity and
accuracy in the female range (19, 20), making assessment
of hyperandrogenism and, consequently, of PCOS pheno-
types imprecise.
The aim of this study was to assess whether either the
different features used for diagnosing PCOS or their com-
binations into the PCOS phenotypes may be helpful in
predicting insulin resistance in these women. To answer
this question, 137womenwith PCOSwere carefully char-
acterized, using state-of-the-art methods.
Subjects and Methods
Subjects
A total of 137 consecutive Caucasian women with PCOS,
recruited in the Verona PCOS Pathophysiology and Phenotype
(Verona 3P) Study, an ongoing project with the aim of building
a detailed resource for assessing the relationships between the
different features of these women, were studied. All of them had
been referred to the Division of Endocrinology, Diabetes and
Metabolism of Verona Hospital, Verona, Italy, for oligoamen-
orrhea and/or hyperandrogenism. Inclusion criteria were a con-
firmed diagnosis of PCOS and age 18 to 40 years. Exclusion
criteria were diabetes mellitus or other diseases or use of medi-
cations that could potentially interfere with the evaluations car-
ried out in the study. In particular, patients should not have
received oral contraceptives, insulin-sensitizing agents, antian-
drogens, or glucocorticoids in the past 6 months.
PCOS was diagnosed according to criteria indicated by the
Rotterdam Workshop (3), ie, the presence of at least 2 of the
following 3 features: clinical and/or biochemical hyperandro-
genism, chronic oligoanovulation, and PCO morphology, after
exclusion of secondary causes. Hyperandrogenism was defined
by presence of hirsutism and/or increased free testosterone.
Acne, alopecia, and serum androgens other than free testoster-
one were not used to diagnose hyperandrogenism, because they
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are less specific and add a limited incremental amount to diag-
nosis of PCOS (1). Chronic oligoanovulation was diagnosed by
presence of either oligoamenorrhea (fewer than9 cycles per year)
or a luteal phase serum progesterone level less than 12 nmol/L.
Inmost cases, progesteronemeasurement was repeated in 2 sub-
sequent menstrual cycles. PCO was diagnosed according to
ESHRE/ASRM recommendations (3). Secondary causes of
PCOS were ruled out by systematic 17-hydroxyprogesterone,
prolactin, and TSH assays.
All the participants gave their written informed consent be-
fore the study, which was conducted according to the Declara-
tion of Helsinki and approved by our institutional ethics
committee.
Protocol
Subjects included in the study underwent complete medical
examination, assessment of endocrine and metabolic features
and glucose tolerance, ultrasound evaluation of ovarian mor-
phology, and measurement of insulin sensitivity.
Medical examination comprised measurement of body
weight andheight,waist circumference, bloodpressure (BP), and
hirsutism score. Elevated BP values were confirmed on 2 occa-
sions.Hirsutismwas assessedby themodifiedFerriman-Gallwey
score, the gold standard for clinical evaluation of hirsutism (21),
with a cutoff point of 8.
Subsequently, in the early follicular phase of a spontaneous
menstrual cycle, or, inwomenwith severemenstrual alterations,
after at least 3 months of amenorrhea, a fasting venous blood
sample was drawn for metabolic and hormonal profile assess-
ment. A standard 75-g oral glucose tolerance test was also per-
formed, withmeasurement of plasma glucose and insulin at fast-
ing and every 30 minutes for 2 hours.
Ovarian morphology was evaluated by 1 of 2 experienced
gynecologists, by a transvaginal approach whenever possible,
with a Voluson 730 PRO device (GE Healthcare, Milwaukee,
Wisconsin), equipped with volumetric 3-dimensional probes.
Ovary volume was calculated using the ellipsoid formula
(length  height  width  /6).
Insulin sensitivity was assessed by the glucose clamp tech-
nique as described previously (22), using a primed insulin infu-
sion rate of 80 mU/m2  min. The duration of the clamp was 120
minutes, and the glucose disposal rate was calculated during the
last 30 minutes, with standard equation (23). Because muscle is
responsible for most insulin-induced glucose metabolism (24),
data are expressed per fat-free mass (FFM). Body composition
was assessed by bioelectrical impedance (Bia-103; Akern, Flor-
ence, Italy) (25).
Metabolic syndrome was diagnosed according to the 2009
Joint Interim Statement of the International Diabetes Federation
(IDF) and other societies (26). This document revised the Adult
Treatment Panel III (ATP III) diagnostic criteria for metabolic
syndrome (27), concluding that the cutoff point for waist cir-
cumference to define abdominal obesity should be  80cm in
women of European origin, as were the women recruited in the
present study.
In 4 women with PCOS (3 with the classic phenotype and 1
with the ovulatory phenotype), glucose clamp studies were not
completed, because of technical problems. Therefore, clamp
data refer to 133 subjects. Metabolic syndrome could be diag-
nosed as present or absent in 134women.Diagnosis in 3 subjects
with the classic phenotype was not possible because of missing
lipid data.
A historical sample of 24 healthy nonhirsute women, with
regular menstrual cycles and normal ovarian morphology,
served as the reference cohort for clampdata,whereas 51women
with the same characteristics served to define the reference in-
terval for serum testosterone.
Assays
Plasma glucose was measured by the glucose-oxidase
method, using a glucose analyzer (YSI-2300 Stat Plus; YSI Inc,
Yellow Springs, Ohio).
Serum total testosterone was measured by liquid chromatog-
raphy-mass spectrometry using a Micromass Quattro Premier
XE Mass Spectrometer (Waters Corporation, Milford, Massa-
chusetts).The limit of quantificationwas2.5ng/dLand the intra-
assay coefficient of variation (CV)was 9.1%at concentration 14
ng/dL, and interassay CV was 9.3% at concentration 26 ng/dL.
The free testosterone fraction was estimated by equilibrium di-
alysis (28, 29); the interassay CV was 8%.
SHBG and insulin were assayed by immunoradiometric
methods (Orion Diagnostica, Espoo, Finland; and Biosource,
Fleurus, Belgium, respectively) and gonadotropins by an auto-
mated chemiluminescent method (Advia Centaur XP; Siemens,
Tarrytown, New York). Serum lipids were determined by stan-
dard laboratory procedures.
Statistical analysis
Continuous variables are described bymedian and interquar-
tile range, because most of them (except for the M-clamp value,
total cholesterol, and BP) were not normally distributed. Cate-
gorical variables are summarized by percentages. Nonnormally
distributed variables were log- or square roottransformed be-
fore analysis.
Comparisons between phenotypes were performed using
1-way ANOVA. Because triglyceride distribution could not be
normalized, values were compared by a nonparametric Kruskal-
WallisANOVA.Multiple post hoc comparisonswere performed
using Bonferroni correction.
Multiple regression was used to assess the relationship be-
tween the M-clamp value as a dependent continuous variable
and the clinical features used in diagnosis of PCOS as indepen-
dent variables. Multiple regression analysis was also used to
compare M-clamp values in subjects belonging to the different
PCOS phenotypes vs the historical sample of healthy women,
which was included as the reference group, to establish whether
insulin sensitivity was abnormal in each PCOS phenotype. The
same analyses were performed with adjustment for age and fat
mass (analysis of covariance).
Logistic regression analyseswere performed to investigate the
associations between the dichotomizedM-clamp variable (insu-
lin resistance present or absent) as a dependent categorical vari-
able and either the PCOS diagnostic features or the PCOS phe-
notypes as independent variables. In a second step, adjustments
for age and fat mass were performed. In these analyses, insulin
resistance was defined by a M-clamp value below the 25th per-
centile (11.75 mg/kg FFM  min) of the distribution in healthy
women, according to the World Health Organization and the
European Group for the Study of Insulin Resistance (EGIR) def-
initions of insulin resistance (30, 31).
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Percentages of women with metabolic syndrome in the dif-
ferent PCOS phenotype groups were compared using the Fisher
exact test.
For power calculation, the primary endpoint was risk of in-
sulin resistance in each PCOSphenotype. From the limited avail-
able literature, the prevalence of insulin resistance in these
women is about 70%(11, 12).Todetect a differencewith respect
to the reference population, in which this prevalence is by defi-
nition 25%,with an error .05 andpower .80 and a 2-sided
test, 19 subjects per group are required.
Analyses were performed using STATA version 10.1 (Stata-
Corp, College Station, Texas).
Results
In thewhole sample of 137womenwith PCOS included in
the study, 84.7% had hyperandrogenism, 84.7% had
chronic oligoanovulation, and 89% had PCO morphol-
ogy. According to the individual combinations of these
features, 95 (69.4%) of these women had the classic phe-
notype, whereas 21 (15.3%) had the ovulatory pheno-
type, and the remaining 21 (15.3%) had the normoan-
drogenic phenotype.
Table 1 shows the main characteristics of the whole
cohort of women with PCOS. The median body mass in-
dex was 28.5 kg/m2. Medians of metabolic features were
in the normal range, except for fasting insulin, which was
increased, and high-density lipoprotein (HDL) choles-
terol, which was marginally decreased. As expected, se-
rum free testosterone was above and SHBG below the
limits of the respective reference range.
The comparison of women belonging to the different
PCOS phenotypes revealed several differences (Table 2).
In particular, compared with the classic phenotype sub-
group, the normoandrogenic subgroup was leaner and
had lower insulin and triglyceride and higher HDL cho-
lesterol and SHBG levels. Moreover, as expected accord-
ing to phenotype definition, the Ferriman-Gallwey score
and serum testosterone level also differed between these
subgroups. Conversely, compared with the classic pheno-
type subgroup, the ovulatory subgroup had lower free
testosterone and triglyceride levels. Comparison of these
latter subgroups also showed notable differences in terms
of anthropometric features, although these did not reach
statistical significance.
Glucose utilization during the clamp (M-clamp value)
was reduced in this cohort of women with PCOS (10.0
3.3 mg/kg FFM  min; reference value in healthy women
11.75 mg/kg FFM  min), showing that most of them
(71.4%) were insulin resistant. The frequency of insulin
resistancewas80.4%,65.0%, and38.1%, respectively, in
the classic, ovulatory, and normoandrogenic phenotype
subgroups (P  .001).
When the relationship between theM-clamp value and
the presence or absence in these women of each specific
PCOS diagnostic featurewas analyzed (Table 3,model 1),
insulin-stimulated glucose utilization was associated with
hyperandrogenism (P .0001) but not with oligoanovu-
lation (P .21) or PCOmorphology (P .15). However,
none of the features of PCOS was independently associ-
atedwith insulin action after inclusion of fat mass and age
in the analysis (Table 3, model 2): only these latter vari-
ables were associated (fat mass negatively and age posi-
tively) with insulin sensitivity.
On the other hand, when subjects with PCOS were
categorized into phenotypes and compared with healthy
women, insulin action was significantly impaired in pa-
tients with either the classic or the ovulatory phenotype,
but not in those with the normoandrogenic phenotype
(Table4, univariable analysis, andFigure1).The inclusion
of fat mass and age in the analysis did not substantially
affect these conclusions: the classic phenotype was still a
predictor of impaired insulin action (P  .003), whereas
the ovulatory phenotype showed borderline significance
(P .051) (Table 4, multivariable analysis). With regard
to this latter finding, statistical significance is fully reached
by using a 1-sided test (P  .026).
When considered as a categorical variable, the presence
of insulin resistance was associated with hyperandro-
Table 1. Main characteristics of the cohort of women
with PCOS included in the study and corresponding
reference intervals
Characteristic
Women with
PCOS (n  137)
Reference
Interval
Age, y 23.0 (19.0–28.0)
Body mass index, kg/m2 28.5 (23.2–34.9) 18.5–24.9
Waist circumference, cm 92.0 (78.0–106.0) 80
Fat mass, kg 26.8 (18.3–38.4)
Fat mass, % 35.3 (29.5–40.7)
FFM, kg 48.3 (42.8–54.8)
Ferriman-Gallwey score 9.0 (4.0–15.0) 8
Systolic BP, mm Hg 120 (110–130) 130
Diastolic BP, mm Hg 80 (70–86) 85
Fasting glucose, mg/dL 85.0 (79.0–92.0) 70–99
Fasting insulin, mU/L 13.3 (7.2–23.3) 9
Total cholesterol, mg/dL 161 (143–182) 200
HDL cholesterol, mg/dLa 48.0 (40.0–58.0) 50
Triglycerides, mg/dLb 67.5 (48.5–108.0) 150
SHBG, nmol/L 29.7 (19.7–45.0) 39–121
LH, IU/L 7.7 (4.7–10.9) 1.0–25.0
FSH, IU/L 5.4 (4.3–6.2) 1.5–11.0
Total testosterone, ng/dL 34.5 (25.3–46.2) 41
Free testosterone, ng/dL 0.60 (0.49–0.93) 0.50
Ovarian follicles, n 13.0 (12.0–16.0) 12
Ovarian volume, mL 10.7 (8.1–13.7) 10
Data are shown as median (interquartile range).
a Available for 133 women
b Available for 136 women.
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genism (odds ratio [OR] 6.03, P .001) and only to a
minor extent (OR  3.12, P  .053) with oligoanovula-
tion, but not with PCOmorphology (Supplemental Table
I published on The Endocrine Society’s Journals Online
web site at http://jcem.endojournals.org). However, after
inclusion of fat mass and age in the model, only body fat
was a significant predictor of insulin resistance in these
women (Supplemental Table I).
On the other hand, when subjects with PCOS were
categorized into phenotypes, insulin resistance proved to
be a feature of both the classic subgroup (OR13.98,P
.001) and the ovulatory subgroup (OR 6.31, P .008),
but not of the normoandrogenic subgroup (Supplemental
Table II). Notably, after inclusion of fat mass and age in
the model (Supplemental Table II), the classic phenotype
was still associated with insulin resistance (OR  5.42,
P  .007), whereas the ovulatory phenotype was not
(OR  3.43, P  .098). However, this latter association
maintained statistical significance in a 1-sided test
(P  .049).
It is noteworthy that32.8%of these youngwomenwith
PCOS met the criteria for diagnosis of metabolic syn-
drome according to the 2009 International Diabetes Fed-
eration statement (Table 5). Among the components con-
tributing to metabolic syndrome diagnosis, increased
waist circumference (73.7%) and low HDL cholesterol
(54.1%) were the most common alterations. Adoption of
Adult Treatment Panel III criteria, which use a higher
waist circumference cutoff value, reduced the frequencyof
abdominal obesity (57.7%) in our cohort, but only mar-
ginally lowered the prevalence of metabolic syndrome
(31.3%).
The metabolic syndrome frequency was higher in
women with the classic phenotype, intermediate in the
ovulatory subgroup, and lower in the normoandrogenic
women (39.1%, 28.6%, and 9.5%, respectively, P 
.030). However, these differences were no longer statisti-
cally significant after adjustment for fatmassandage (data
not shown).
Discussion
This study characterized accurately and comprehensively
a large sample of women with PCOS, using state-of-the-
art methods, to assess which features predict insulin re-
sistance in these subjects. This is a relevant issue, because
PCOS is aheterogeneous condition, and it remains unclear
Table 2. Main characteristics of the women with PCOS subdivided according to the PCOS phenotypes
Classic
(n  95)
Ovulatory
(n  21)
Normoandrogenic
(n  21)
P by
ANOVA
Age, y 23.0 (19.0–28.5) 24.0 (19.7–27.0) 26.0 (23.5–29.0) .340
Body mass index, kg/m2 30.4 (25.5–36.5) 26.1 (22.9–33.4) 21.6 (20.4–27.2)a <.001
Waist circumference, cm 96.0 (78.0–106.0) 85.0 (77.0–101.6) 76.0 (68.7–85.5)a <.001
Fat mass, kg 28.9 (21.8–40.7) 25.6 (17.8–35.6) 17.4 (14.0–23.8)a <.001
Fat mass, % 36.4 (32.0–42.1) 33.6 (29.7–40.4) 29.0 (24.7–34.3)a .001
FFM, kg 50.3 (44.9–56.8) 47.3 (42.0–52.1) 42.6 (39.7–44.8)a <.001
Ferriman-Gallwey score 11.0 (5.0–16.0) 9.0 (7.7–15.6) 3.0 (2–4)a, b <.001
Systolic BP, mm Hg 120 (110–130) 120 (114–128) 118 (110–126) .355
Diastolic BP, mm Hg 80 (70–88) 80 (73–85) 75 (67–84) .368
Fasting glucose, mg/dL 86.0 (81.0–94.0) 83.0 (79.0–90.5) 83.0 (77.7–88.7) .269
Fasting insulin, mU/L 16.1 (9.0–25.8) 11.8 (7.4–19.4) 7.3 (5.3–10.0)a <.001
Total cholesterol, mg/dL 161 (149–188) 150 (136–162) 166 (149–178) .131
HDL cholesterol, mg/dLc 47.0 (38.0–54.2) 50.0 (42.5–54.5) 61.5 (49.5–70.0)a .002
Triglycerides, mg/dLd 80.5 (53.0–113.0) 54.0 (44.2–73.0)e 53.0 (39.0–64.0)e .007
SHBG, nmol/L 25.7 (18.2–37.9) 28.8 (20.4–44.4) 47.5 (35.7–66.9)a, f <.001
LH, IU/L 7.8 (4.7–12.0) 5.6 (3.5–8.6) 8.7 (5.3–14.6)f .034
FSH, IU/L 5.3 (4.3–6.0) 5.8 (3.8–6.2) 5.9 (4.8–6.9) .073
Total testosterone, ng/dL 39.1 (27.7–48.0) 30.4 (23.5–37.2) 28.5 (22.6–38.1)e .028
Free testosterone, ng/dL 0.74 (0.54–1.02) 0.56 (0.50–0.66)e 0.43 (0.33–0.46)a, b <.001
Ovarian follicles, n 13.0 (12–15) 12.0 (8.5–13.0) 14.0 (12.7–18.2) .085
Ovarian volume, mL 11.5 (8.6–13.8) 8.4 (6.5–12.7) 10.1 (7.8–13.3) .158
Data are shown as median (interquartile range). Statistically significant P values are in bold.
a P  .001 vs classic PCOS.
b P  .001 vs ovulatory PCOS.
c Not available in 3 subjects with the classic phenotype and 1 subject with the ovulatory phenotype.
d Not available in 1 subject with the classic phenotype.
e P  .05.01 vs classic PCOS.
f P  .05.01 vs ovulatory PCOS.
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how the metabolic risk stratifies among the subjects who
are affected. In particular, we investigatedwhether insulin
resistance is associated either with each single PCOS di-
agnostic feature, as currently defined by the Rotterdam
workshop (3), or with their aggregation into the PCOS
phenotypes, which originate from the different possible
combinations of these features.
Our data confirmed that insulin resistance is a common
characteristic ofwomenwithPCOS,present inabout70%
of our study population. However, the novel finding was
that after adjustment for relevant confounding factors,
such as body fat and age (32, 33), insulin resistance ap-
peared to be a specific feature of the classic phenotype and
toa lesser extent of theovulatoryphenotype, but not of the
normoandrogenic phenotype. On the other hand, the im-
pairment in insulin action was not independently associ-
atedwith any single diagnostic feature of PCOS. It is note-
worthy that similar conclusions were reached when the
clamp-derivedmeasure of insulin sensitivity was analyzed
either as a categorical or as a continuous variable, exclud-
ing a possible pitfall due to the arbitrary definition of an
insulin resistance cutoff point.
According to the conclusions of both the ESHRE/
ASRM Rotterdam workshop (3) and the AE-PCOS con-
sensus statement (1), PCOS remains a syndrome and,
therefore, no single diagnostic feature is sufficient per se
for clinical diagnosis. Notably, our data now show that
this concept also applies to the association between diag-
nostic features of PCOS and insulin resistance. It is note-
worthy that similar conclusions were reached previously
regarding blood concentrations of advanced glycation
end-products, which are potential links between the met-
abolic and reproductive abnormalities of women with
PCOS and were found to be higher in these subjects than
in those with isolated components of the syndrome and
healthy control subjects (34).
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Figure 1. Box plots of the M-clamp values measured in the women
with PCOS included in the study, subdivided into the PCOS
phenotypes. Data are compared with reference values for healthy
control subjects. *P  .013 vs healthy control subjects; **P  .001 vs
healthy control subjects; †P  .001 vs normoandrogenic phenotype.
Table 3. Multiple regression analysis for the
association between the different clinical elements used
in diagnosis of PCOS and insulin sensitivity
Featurea
b
Coefficient SE P
Model 1
Hyperandrogenism 2.920 0.78 <.001
Oligoanovulation 1.135 0.91 .213
PCO morphology 1.303 0.90 .150
Model 2
Hyperandrogenism 1.179 0.68 .084
Oligoanovulation 0.049 0.75 .948
PCO morphology 1.060 0.74 .153
Age in y 0.120 0.04 .005
Fat mass in kg 0.128 0.02 <.001
Insulin sensitivity was measured by M-clamp (insulin-stimulated glucose
utilization during the clamp, mg/kg FFM  min) and considered as a
continuous variable. Statistically significant P values are in bold.
a Model 1 includes only PCOS-specific clinical elements. Model 2
includes PCOS-specific clinical elements adjusted by age and fat mass.
Table 4. Regression analysis for the association between the different phenotypes of PCOS and insulin sensitivity
Univariable Analysis Multivariable Analysis
b
Coefficient SE P
b
Coefficient SE P
PCOS phenotype vs
healthy women
Classic 4.31 0.73 <.001 2.13 0.70 .003
Ovulatory 2.97 0.95 .002 1.66 0.84 .051
Normoandrogenic 1.22 0.94 .197 0.62 0.81 .451
Age in y 0.15 0.05 .003 0.10 0.04 .016
Fat mass in kg 0.14 0.02 <.001 0.11 0.02 <.001
Insulin sensitivity was measured by M-clamp (insulin-stimulated glucose utilization during the clamp, mg/kg FFM  min) and considered as a
continuous variable. Statistically significant P values are in bold.
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Our findings provide useful informationwith regard to
2 relevant, still open questions: first, whether nonclassic
phenotypes really merit inclusion in the PCOS diagnosis;
and second, whether all women with PCOS should be
uniformly screened for metabolic abnormalities.
With regards to the first question, because there is no
unequivocal method to diagnose PCOS, any criteria are
questionable. Nonetheless, if the metabolic dysfunction
and the associated risks are considered central issues, then
our findings suggest that the so-called normoandrogenic
phenotype should be considered a separate condition.
With regard to the second question, our data support
the conclusion that phenotype distinction may guide phy-
sicians in designing cost-effective strategies for screening
of metabolic risk upon diagnosis of PCOS and may pos-
sibly also guide treatments aimed to prevent themetabolic
complications of this condition.
This issue has been investigated in a body of literature.
With regard to the single diagnostic features,many studies
reported an association between hyperandrogenism and
insulin resistance (35–38), whereas data regarding oligo-
anovulation were more contradictory (38, 39). On the
other hand, the studies that assessed the relationship be-
tween insulin resistance and ovarian morphology gener-
ally did not support the existence of increased metabolic
dysfunction among women with polycystic ovaries (35,
38, 40–44). Nonetheless, some authors reported an as-
sociation between PCO morphology and either reduced
(39, 45) or increased insulin sensitivity (46, 47).
With regard to PCOS phenotypes, most previous stud-
ies reported that women with the classic phenotype were
more insulin resistant than thosewith either the ovulatory
(43, 48–53) or the normoandrogenic phenotype (35, 37,
41, 43, 47, 50, 52, 54). However, several studies did not
confirm these findings (55–63). The comparison of the
ovulatory and the normoandrogenic phenotypes gave
even more discordant results (43, 50, 52–54, 61, 63).
Moreover, in the comparisons with control women with-
out PCOS, although the classic phenotype subgroup gen-
erally appeared to be insulin resistant (41, 43, 48–50, 52,
56, 58, 61, 63, 64), discrepancies were still found with
regard to both the ovulatory (43, 48–54, 59, 61, 63) and
the normoandrogenic (41, 43, 49, 50, 52–54, 56, 58, 61,
63) phenotype subgroups.
Unfortunately, interpretation of all these studies is con-
strained by several limitations. In particular, all of them
used surrogate measures of insulin sensitivity, which do
not predict accurately the gold standard measurement of
insulin action obtained by the glucose clamp (15–18, 65).
Many reports were also flawed by the inaccuracy of rou-
tine platform assays for testosterone and other androgens
(19, 20). The imprecise assessment of one of the cardinal
features on which diagnosis of PCOS is based may have
affected classification of subjects into the PCOS pheno-
types or even caused inappropriate inclusion or exclusion
of some women into the PCOS diagnosis (1). Moreover,
several studies did not take into account differences in
body composition among subjects. This is a crucial issue
in women with PCOS, because hyperandrogenism ap-
pears tobe linked to an excess of body fat (8). Finally, none
of these studies included all diagnostic features of PCOS
together in the analysis. These limitationsweaken the con-
clusions of previous research andmay also account for the
inconsistencies among studies.
Notably, in our cohort of PCOS women, the relation-
ship between age and insulin sensitivity showed an unex-
pected positive direction, in contrast with previous find-
ings in the general population (32, 66). A possible
explanation for this unique phenomenon is attenuation
with age of all diagnostic features of PCOS, as reported by
several authors (67–71). We can thus speculate that our
findingsmaybe linked to less severePCOSclinical features
in older women. If this hypothesis is true, a primary role
for one or more diagnostic features of PCOS in the im-
pairment of insulin action would be supported.
The major strength of this study is the careful charac-
terization of women with PCOS, in particular the use of
state-of-the-art methods to robustly assess insulin sensi-
Table 5. Number (and percentage) of women with PCOS with metabolic syndrome and with each clinical
components contributing to metabolic syndrome diagnosis in the entire cohort of subjects and in women subdivided
according to their PCOS phenotypes
All Women
with PCOS
PCOS Phenotypes
Classic Ovulatory Normoandrogenic
Metabolic syndromea 44 (32.8) 36 (39.1) 6 (28.6) 2 (9.5)
Fasting glucose 100 mg/dL 15 (10.9) 10 (10.5) 3 (14.3) 2 (9.5)
HDL cholesterol 50 mg/dL 72 (54.1) 58 (62.4) 9 (45.0) 5 (25.0)
Triglycerides 150 mg/dL 17 (12.5) 13 (13.8) 1 (4.8) 3 (14.3)
Waist 80 cm 101 (73.7) 80 (84.2) 15 (71.4) 6 (28.6)
BP 130/85 mm Hg 49 (36.0) 38 (40.4) 6 (28.6) 5 (23.8)
a Because of missing values for some subjects (see footnotes to Tables 1 and 2), 134 of 137 women with PCOS have been included in the analysis
of metabolic syndrome frequency. All missing subjects had the classic phenotype.
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tivity and hyperandrogenism. This assessment adds more
validity to the argument that there is a scale of metabolic
risk amongPCOSphenotypes.Although, to thebest of our
knowledge, this is the largest published study to use the
gold standard technique to measure insulin sensitivity in
these women, the number of subjects with the nonclassic
phenotypes was still limited. Moreover, extrapolation of
these findings to non-Caucasian women with PCOS
should be undertaken with caution.
In conclusion, insulin resistance is a common feature in
womenwith PCOS.However, there is a scale ofmetabolic
risk in these subjects. Although no single diagnostic fea-
ture of PCOS is independently associated with impaired
insulin action, the combinations of these features, which
define PCOS phenotypes, may allow physicians to estab-
lish which women merit screening for metabolic dysfunc-
tion. From a metabolic point of view, women with the
normoandrogenic phenotype behave as a separate group.
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